| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/1352458512463768 |
| P698 | PubMed publication ID | 23100527 |
| P50 | author | Hans-Peter Hartung | Q30001859 |
| Bernd C Kieseier | Q64731348 | ||
| P2093 | author name string | Bernd Turowski | |
| Sebastian Jander | |||
| P2860 | cites work | Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis | Q24648404 |
| Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab | Q26851341 | ||
| Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report | Q34963426 | ||
| Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence? | Q48622816 | ||
| Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder | Q48795303 | ||
| P433 | issue | 11 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 1650-1652 | |
| P577 | publication date | 2012-11-01 | |
| P1433 | published in | Multiple Sclerosis Journal | Q1952449 |
| P1476 | title | Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod | |
| P478 | volume | 18 |
| Q30578046 | A rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann's syndrome |
| Q38152451 | Bridging, switching or drug holidays - how to treat a patient who stops natalizumab? |
| Q99711396 | Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis |
| Q89359174 | Catastrophic Magnetic Resonance Images in the Central Nervous System of Patients Undergoing Treatment with Fingolimod |
| Q33562198 | Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation |
| Q45967844 | Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions. |
| Q26771635 | Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis |
| Q33583306 | Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation |
| Q50860736 | Differential effects of fingolimod on B-cell populations in multiple sclerosis. |
| Q64271793 | Fingolimod Alters Tissue Distribution and Cytokine Production of Human and Murine Innate Lymphoid Cells |
| Q37725909 | Fingolimod after natalizumab and the risk of short-term relapse |
| Q26752466 | Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence |
| Q58793277 | Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod |
| Q39320418 | Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events |
| Q26781389 | Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities |
| Q41553443 | Neurological safety of fingolimod: An updated review |
| Q51218322 | Observational Study of Switching from Natalizumab to Immunomodulatory Drugs. |
| Q30458371 | Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis |
| Q35659134 | Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod |
| Q47096340 | Pattern Recognition of the Multiple Sclerosis Syndrome |
| Q35547287 | Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod |
| Q50949572 | Reduction of the washout time between natalizumab and fingolimod. |
| Q91884302 | Regulation of lymphocyte trafficking in central nervous system autoimmunity |
| Q54375890 | Reply to letter to the editor: Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder by Pitarokoili and Gold. |
| Q36975701 | Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis |
| Q42374227 | S1P1 deletion differentially affects TH17 and Regulatory T cells |
| Q45977173 | Switching therapies in multiple sclerosis. |
| Q44061291 | The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders |
| Q34330211 | Treating multiple sclerosis with monoclonal antibodies: a 2013 update |
| Q38075462 | Tumefactive demyelination: an approach to diagnosis and management |
| Q26777684 | Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment |
| Q54761661 | Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others? |
| Q38177842 | We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it? |
Search more.